Year: 2024
Type: article
Abstract: Waldenström macroglobulinaemia (WM) is a unique, cluster of differentiation (CD) 20+ B-cell malignancy, with a characteristic immunoglobulin M-secreting lymphoplasmacytic bone marrow infiltrate that is bolstered by a highly supportive microenvironment, including upregulated programmed death 1 expression. However, the impact of checkpoint inhibition in WM is unclear. Commentary on: Kothari et al. PembroWM: A phase II trial to investigate the safety and efficacy of rituximab and pembrolizumab in relapsed/refractory Waldenström's macroglobulinaemia. Br J Haematol 2024; 205:2273-2281.
Source: British Journal of Haematology
DOI: 10.1111/bjh.19844
Author: Prashant Kapoor
Institution: Mayo Clinic
Language: English
Subfield: Genetics
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W4404120037